Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: Results from a large Japanese postmarketing surveillance study

Takao Koike, Masayoshi Harigai, Shigeko Inokuma, Naoki Ishiguro, Junnosuke Ryu, Tsutomu Takeuchi, Yoshiya Tanaka, Hisashi Yamanaka, Koichi Fujii, Takunari Yoshinaga, Bruce Freundlich, Michio Suzukawa

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Finding an effective treatment strategy for rheumatoid arthritis (RA) patients who have not benefited from previous tumor necrosis factor-α antagonist treatment is important for minimizing RA disease activity and improving patient outcomes. The aim of this study was to compare the safety and effectiveness of etanercept in patients with and without infliximab (IFX) treatment experience. Patients (n = 7,099) from a large postmarketing observational study of etanercept use in Japan were divided into 2 cohorts based on previous IFX use (pre-IFX and non-IFX). Baseline characteristics were assessed in each cohort. Adverse events (AEs) and European League Against Rheumatism (EULAR) responses were monitored every 4 weeks for 24 weeks. At baseline, pre-IFX patients were younger and had fewer comorbidities and a shorter RA duration than non-IFX patients. During the study, pre-IFX patients received concomitant methotrexate more often than non-IFX patients. The incidence of AEs and serious AEs were significantly lower in pre-IFX patients, as was the percentage of patients who discontinued treatment. Both cohorts had significant improvement (P<0.001) in EULAR responses at the end of the treatment period. This study demonstrated that etanercept was effective and well tolerated in active RA patients with and without prior IFX treatment.

Original languageEnglish
Pages (from-to)1617-1624
Number of pages8
JournalRheumatology International
Volume32
Issue number6
DOIs
Publication statusPublished - 2012 Jun 1

Keywords

  • Etanercept
  • Infliximab
  • Postmarketing surveillance study
  • Rheumatoid arthritis
  • TNF-α antagonists

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology

Fingerprint Dive into the research topics of 'Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: Results from a large Japanese postmarketing surveillance study'. Together they form a unique fingerprint.

  • Cite this

    Koike, T., Harigai, M., Inokuma, S., Ishiguro, N., Ryu, J., Takeuchi, T., Tanaka, Y., Yamanaka, H., Fujii, K., Yoshinaga, T., Freundlich, B., & Suzukawa, M. (2012). Safety and effectiveness of switching from infliximab to etanercept in patients with rheumatoid arthritis: Results from a large Japanese postmarketing surveillance study. Rheumatology International, 32(6), 1617-1624. https://doi.org/10.1007/s00296-011-1807-0